Last reviewed · How we verify
NCT06718959
Efficacy and Safety Evaluation of Jet Floss EX After 8-week Application
NA trial testing the test product (Jet Floss EX) in Bleeding on Probing in 72 participants. Completed in 17 June 2024.
17 June 2024
Quick facts
| Lead sponsor | Guang Dong Bixdo Health Technology Co.,Ltd |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 72 |
| Start date | 9 April 2024 |
| Primary completion | 17 June 2024 |
| Estimated completion | 17 June 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- the test product (Jet Floss EX)
- the control product (interdental brush)
Conditions studied
- Bleeding on Probing — all drugs for Bleeding on Probing →
- Plaque — all drugs for Plaque →
- Gingival Index — all drugs for Gingival Index →
Sponsor
Guang Dong Bixdo Health Technology Co.,Ltd
Who can join
Adults 18 to 60, any sex, with Bleeding on Probing or Plaque. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This was a single center, comparison among treatments, 8-week study of the efficacy and safety of Jet Floss EX. Totally 72 eligible subjects were recruited in this study and randomly divided into 2 groups. During wash out phase (7 days before the study), subjects used distributed manual toothbrush and toothpaste every morning and evening to replace their own products. After that, subjects screened by dentist to ensure met the inclusion criteria. During treatment phase, for group1 (treatment group), subjects continued to use distributed manual toothbrush and toothpaste every morning and evening, and add used the test product (Jet Floss EX) twice a day. For group2 (control group), subjects continued to use distributed manual toothbrush and toothpaste every morning and evening, and add used auxiliary product (interdental brush) twice a day. During the study, any other oral care products and non-emergency oral treatment were not allowed. Test Objective:To evaluate the efficacy and safety of test product by means of intraoral exams of BOP, PD, MGI, RMNPI, hard and soft tissues exams and selfassessment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06718959
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06718959 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Guang Dong Bixdo Health Technology Co.,Ltd
- Last refreshed: 5 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06718959.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing